Research Site
Varvsgatan, Lulea, Sweden
NCT Number: NCT00688402
The purpose of the study is to compare different formulations of AZD3355 in regard to possible adverse events such as sensations of numbness, tinglings and heat in the skin.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Varvsgatan, Lulea, Sweden
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single dose
Other names: Lesogaberan
Time frame: During 0-4 hours post dose
Time frame: Frequent sampling up to 36 hours post dose
Time frame: During the whole treatment period
AstraZeneca
Industry
A Double-blind, Randomized, Cross-over Design, Phase 1 Pharmacodynamic Study to Investigate the Effect of Different Formulations of AZD3355 for the Development of Paresthesiae After Dosing in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07560787
Body Weight, Deglutition Disorders
Van, Turkey (Türkiye)
View Trial DetailsNCT05107219
Barrett Esophagus, Deglutition Disorders
Scottsdale, Arizona, United States
View Trial DetailsNCT06585176
Deglutition Disorders, Digestive System Diseases
Xiamen, Fujian, China
View Trial DetailsNCT06945237
Deglutition Disorders, Digestive System Diseases
Shanghai, Shanghai Municipality, China
View Trial Details